Virax Biolabs Group Limited

Stage 4 · Declining · week 12

As of Oct 22, 2026, Virax Biolabs Group is in Stage 4, the downtrend phase, now in week 12 (since Jul 30, 2026). It closed at $1.24, 92.8% below its 52-week high and below its 200-day average, which is falling.

$1.24

-7.84% today

$1.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VRAX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 41w

S4 65w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 41w → S1 9w → S2 12w → S3 9w → S2 5w → S3 4w → S4 65w → S1 5w → S4 1w → S1 2w → S4 12w current

Total tracked: 166 weeks across 12 stage runs.

VRAX among Biotechnology522nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…522	VRAXVirax Biolabs Group Limited	Stage 4 · wk 12	6	−51.6%

vs 52W High

-92.8%

$1.24 lo$17.20 hi

92.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 12

1w13w26w

Week 12, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-70.2%

200 DMA: $4.14 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.08x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-51.6%

-61.3%

-68.9%

YTD

-87.1%

-92.3%

Scan Membership

Breakout Watch

Latest: 2025-01-02

2 appearances in last 60 days. First seen: 2024-08-07.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 12 · Vol 0.08x

2026-10-21S4

Wk 12 · Vol 0.03x

2026-10-20S4

Wk 12 · Vol 0.03x

2026-10-19S4

Wk 12 · Vol 0.03x

2026-10-16S4

Wk 12 · Vol 0.08x

2026-10-15S4

Wk 11 · Vol 0.09x

2026-10-14S4

Wk 11 · Vol 0.08x

2026-10-13S4

Wk 11 · Vol 0.08x

2026-10-12S4

Wk 11 · Vol 0.14x

2026-10-09S4

Wk 11 · Vol 0.18x

2026-10-08S4

Wk 10 · Vol 0.10x

2026-10-07S4

Wk 10 · Vol 0.56x

Moving averages & range

50 DMA

$2.39

200 DMA

$4.14

52W High

$17.20

52W Low

$1.24

5D Low

$1.24

Resistance levels (recent highs)

20d High

$2.40

60d High

$3.45

120d High

$7.98

250d High

$17.20

Next resistance

+94.3%

to 20d High

ROE

-78.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.1

Virax Biolabs Group: quick answers

What stage is Virax Biolabs Group in?

As of Oct 22, 2026, Virax Biolabs Group (VRAX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 30, 2026 and is in week 12. What the four stages mean

Is Virax Biolabs Group in an uptrend?

No. Virax Biolabs Group is in a Stage 4 downtrend. It trades 70.2% below its 200-day average, which is falling.

How far is Virax Biolabs Group from its 52-week high?

Virax Biolabs Group closed at $1.24 on Oct 22, 2026, 92.8% below its 52-week high of $17.20. Its 52-week low is $1.24.

How has Virax Biolabs Group performed over the past year?

As of Oct 22, 2026, Virax Biolabs Group is down 92.3% over the past year and down 87.1% so far in 2026.

Which sector and industry is Virax Biolabs Group in?

Virax Biolabs Group is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.